Can two existing drugs keep eye cancer from spreading?
NCT ID NCT02068586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether sunitinib or valproic acid can prevent uveal melanoma, a rare eye cancer, from spreading to other parts of the body in high-risk patients. 210 participants who have already had their primary tumor treated are randomly assigned to receive one of the drugs or a combination. The study tracks how long they live without the cancer returning or spreading.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sunitinib and valproic acid
- What this could lead to
- If successful, this could show that taking sunitinib or valproic acid after initial treatment helps prevent uveal melanoma from spreading to other organs, potentially improving survival.
- What could go wrong
- This is a phase 2 trial, so results are still preliminary. The drugs may not work better than no treatment, and side effects like fatigue, nausea, or liver problems could occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CILIARY BODY AND CHOROID MELANOMA, MEDIUM/LARGE SIZE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.